Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

This study tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with standard chemotherapy is safe and effective for people with advanced lung cancer (non-small cell type) who also have HIV. People with HIV are often excluded from cancer trials, and this study specifically includes them. **You may be eligible if...** - You have stage IV non-small cell lung cancer (advanced lung cancer) - You have not yet received chemotherapy for your advanced-stage lung cancer - You are living with HIV and have been on effective HIV medications (antiretroviral therapy) for at least 4 weeks - Your HIV viral load is below 400 copies/mL - You have had no AIDS-defining infections in the past year **You may NOT be eligible if...** - You have received prior systemic therapy for your advanced lung cancer - Your HIV is not well-controlled on medications - You have had prior treatment with immunotherapy drugs - You have active autoimmune disease Talk to your doctor to see if this trial is right for you.